Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Age 0-18 years old, with legal guardian;
• Clinically suspected or confirmed patients with neuroblastoma;
• If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent.
Locations
Other Locations
China
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING
Hangzhou
Contact Information
Primary
Peipei Wang, MD
wpp199411@163.com
86 18511395988
Time Frame
Start Date: 2025-02-04
Estimated Completion Date: 2029-12
Participants
Target number of participants: 200
Treatments
18F-MFBG PET/CT in Neuroblastoma
Each patient receive a single intravenous injection of 18F-MFBG 2-5 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Zhejiang University